Wait — it's the day I take the loan from the 'family friend' investor.

Arthur’s paternal smile didn't immediately vanish, but it stiffened around the corners, the microscopic muscles beneath his eyes twitching like fine wires under tension.

"Leo?" Arthur laughed, a soft, self-deprecating sound that had disarmed boardroom adversaries for forty years. "What are you doing, son? We spent three hours walking through the term sheet on Tuesday. Four million principal, subordinated mezzanine structure, interest capitalized at maturity. It’s the exact National Venture Capital Association model. You don't need to read the boilerplate."

"If it's boilerplate, Arthur," I said, pulling a mechanical pencil from my breast pocket, "then another twenty minutes won't change the terms."

I didn't look up. I adjusted my reading glasses and smoothed down Page 1.

The conservatory was dead silent except for the howling Chicago wind rattling the Victorian glass panes. Across the table, Arthur sat back in his velvet armchair, his manicured hands resting over his stomach, his thumb tracing the gold rim of his signet ring.

Click. Tap. Click.

The sound of his ring against the mahogany was the only sign of his rising irritation.

In my first life, I had believed that legal contracts were merely technical translations of human trust. I had believed that when an older man who used to bounce you on his knee said “we’re family,” the words possessed spiritual weight.

Now, I knew that in corporate finance, sentimentality was just a lubricant for theft.

I turned past the recitals. I skipped the corporate definitions.

Page 14: Section 4 – Representations and Warranties of the Borrower.

Standard language regarding corporate standing, intellectual property title, and tax status. Clean. Meticulously drafted by his powerhouse law firm on LaSalle Street.

I kept reading, my pencil moving down the dense margins.

Page 38: Section 8 – Events of Default.

Here was the first subtle needle hidden in the velvet cushion.

Subsection 8.2(f): “Any change, modification, or regulatory procedural inquiry initiated by the United States Food and Drug Administration regarding Phase II clinical protocols shall constitute an immediate, non-curable Event of Default, without requirement of notice or thirty-day cure period.”

My breath caught behind my ribs.

An inquiry. Not a rejection. Not a clinical hold. A routine, procedural inquiry—the standard administrative questions the FDA asked ninety-nine percent of all novel cellular therapies—would legally classify my company as being in default.

And once in default, Section 9 granted the lender the unilateral right to accelerate the entire four-million-dollar principal balance within forty-eight hours.

If the FDA asked for a clarification on our temperature-logging sensors, Arthur had the contractual authority to demand four million dollars in cash by Friday afternoon—knowing full well that our treasury account held less than two hundred thousand.

"Arthur," I said softly, my eyes remaining fixed on Subsection 8.2(f).

"Yes, Leo?" he replied, his tone smooth as polished marble.

"Why does a standard, non-dilutive bridge loan classify an FDA informational inquiry as an immediate, non-curable default?"

The clicking of his signet ring stopped.

The conservatory air suddenly dropped five degrees.

Arthur didn't shift in his chair, but the warmth in his hazel eyes completely evaporated, replaced by the cool, assessing detachment of a loan shark inspecting collateral.

"That's standard risk mitigation for clinical-stage biotech, Leo," Arthur said smoothly, waving his hand as if swatting away a gnat. "Family office capital cannot be exposed to open-ended regulatory liabilities. My risk committee insisted on that language. If the FDA raises questions, the debt needs to be ring-fenced. But as long as your science is sound, you have nothing to worry about. We’re partners."

"A partner gives you thirty days to answer an email, Arthur," I replied, pressing the lead of my pencil against the paper and drawing a thick, deliberate red line through the entire subsection. "A predator gives you forty-eight hours to forfeit your life."

Arthur’s eyes narrowed into razor-thin slits.

The paternal mask was fracturing at the edges, revealing the iron skull underneath.

"You're redlining my execution draft, Leo?" Arthur’s voice dropped into an icy, subterranean register. "Ten minutes before the Federal Reserve wire window closes? Do you have any idea how many founders in this city would crawl across broken glass for four million dollars of clean liquidity on a Thursday morning?"

"I'm not finished reading yet, Arthur," I said, turning to Page 72.

"Leo, your payroll clears tomorrow at midnight," Arthur whispered, leaning forward over the table, his breath carrying the sweet, heavy scent of almond. "If the funds aren't in your Silicon Valley Bank account by two o'clock today, your automated clearinghouse flags the deficit. Your thirty-six researchers walk out. Your cell lines thaw. By Monday morning, Vance Bio-Dynamic is a carcass rotting in the bankruptcy court on Dearborn."

He tapped the table with his knuckles.

Thud. Thud.

"Sign the paper, Leo. Stop playing courtroom drama and let me save your father’s legacy."

I ignored him entirely. My eyes were already scanning the annexes.

And there it was.